Partial
Needs Revision
Patient Risk:
Moderate
Summary
Several claims are partially supported or unsupported because the provided label excerpts do not include the specific surgical/orthopedic/bunion/intercostal/herniorrhaphy/iliotibial band/tarsal tunnel indications stated by the AI. Safety statements are directionally consistent for common adverse reactions and serious cardiovascular/neurologic events, but the provided excerpts do not support other mechanistic or patent-timing claims.
Category Scores
Accurate Statements
Common side effects of EXPAREL include nausea.
Section 6.1: Most common adverse reactions (≥10%) include nausea.
Common side effects of EXPAREL include constipation.
Section 6.1: Most common adverse reactions (≥10%) include constipation.
Common side effects of EXPAREL include headache.
Section 6.1 (placebo-controlled nerve block studies): headache reported (e.g., 5.1%); also Table 1 includes headache.
Rare but serious side effects of EXPAREL can include cardiovascular events.
Section 5.1/5.2: warnings about cardiac toxicity; Section 6.1 (placebo-controlled nerve block studies): tachycardia/bradycardia.
Rare but serious side effects of EXPAREL can include neurological events.
Section 5.1/5.2: warnings about neurological toxicity; Section 6.1 (placebo-controlled nerve block studies): motor dysfunction and other nervous system disorders.
Rare but serious side effects of EXPAREL can include allergic reactions.
Not supported by provided excerpts. (This statement is therefore not listed as accurate; included here only if the label excerpts contained it. They do not.)
Unsupported Statements
EXPAREL is a non-opioid local anesthetic.
Not supported or contradicted by provided excerpts (no statement about opioid/non-opioid in the excerpts).
EXPAREL works by diffusing slowly from a liposome to provide pain relief for up to 72 hours following surgery.
Mechanism/timing claim (diffusing slowly; up to 72 hours) not supported by provided excerpts. Section 12.3 reports systemic plasma levels after dosing at multiple timepoints, but 72-hour pain relief via diffusion is not stated.
EXPAREL’s sustained release mechanism distinguishes it from bupivacaine hydrochloride, which provides only short-acting pain relief.
Not supported by provided excerpts; no comparative duration/“only short-acting” statement.
EXPAREL is indicated for postoperative pain management.
Partially overlaps with labeled 'postsurgical' analgesia but the exact claim 'postoperative pain management' is not directly supported as written. Provided label is specific to postsurgical local analgesia (infiltration) and specified regional nerve blocks.
EXPAREL is approved for infiltration into the surgical site for orthopedic procedures.
Not supported by provided excerpts. The label excerpt specifies postsurgical local analgesia via infiltration (age ≥6) but does not mention 'orthopedic procedures' broadly.
EXPAREL is approved for injection into the surgical site for orthopedic procedures.
Not supported by provided excerpts. The label excerpt does not state orthopedic procedures for 'injection into the surgical site' as a category.
EXPAREL is approved for intercostal nerve block for the surgical site of a rib.
Contrary/unsupported: provided excerpt in Section 14.1 notes additional studies did not provide sufficient data to support an indication for intercostal nerve block.
EXPAREL is approved for injection into the site of incision for a bunionectomy.
Not supported by provided excerpts. No bunionectomy/incision-site procedure-specific indications are included.
EXPAREL is approved for injection into the site of incision for soft tissue dissection.
Not supported by provided excerpts. No soft tissue dissection procedure-specific indication is included.
EXPAREL is approved for injection into the site of incision for herniorrhaphy.
Not supported by provided excerpts. No herniorrhaphy procedure-specific indication is included.
EXPAREL is approved for injection into the site of incision for an iliotibial band.
Not supported by provided excerpts. No iliotibial band procedure-specific indication is included.
EXPAREL is approved for injection into the site of incision for tarsal tunnel release.
Not supported by provided excerpts. No tarsal tunnel release procedure-specific indication is included.
Companies seeking to market a generic version of EXPAREL would need to submit an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the branded product.
Not supported by provided excerpts (no regulatory/ANDA/bioequivalence content in labeling excerpts).
Rare but serious side effects of EXPAREL can include allergic reactions.
Not supported by provided excerpts. Provided adverse reaction excerpts list nausea/constipation/vomiting and specific neurologic/cardiac events, but do not mention allergic reactions.
EXPAREL’s primary patent is expected to expire in 2025.
Not supported by provided excerpts (no patent information in labeling excerpts).
Contradictions
High
AI Statement
EXPAREL is approved for intercostal nerve block for the surgical site of a rib.
Label Reference
Section 14.1 / 14.4: Additional studies did not provide sufficient efficacy and/or safety data to support an indication for intercostal nerve block.
Important Omissions
The label excerpt provides specific indication scope (infiltration in patients aged ≥6; regional nerve blocks in adults limited to interscalene brachial plexus, sciatic in popliteal fossa, and adductor canal) and explicit limitations of use for other nerve blocks; the AI claims include multiple procedure-specific/route-specific indications that are not supported by the provided excerpts and omit the stated limitations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported indication expansion (including an intercostal nerve block claim that conflicts with the provided limitation) could drive off-label use despite label restrictions. Other safety claims are broadly consistent for common and serious cardiac/neurologic events, but unsupported allergic reaction and patent/ANDA claims are not directly patient-risk relevant.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Multiple procedure-specific and nerve-block indication claims are not supported by the provided label excerpts; one claim (intercostal nerve block) conflicts with the provided label limitation.
Suggested Improvement
Restrict indication language to the label excerpted scope: postsurgical local analgesia via infiltration (age ≥6) and postsurgical regional analgesia via perineural blocks limited to interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block in adults; avoid adding procedure-specific indications not present in the excerpt; remove or revise conflicting intercostal nerve block claim.